Laxmi Organic Industries Limited has informed the Exchange about Transcript
LXCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Revenue declined ~4% YoY in Q1 FY26 despite 8% volume growth, with PAT at ₹214 million (3.1% margin vs 4.8% last year). Essentials grew 4% on 11% volume growth but was offset by 7% price decline (linked to lower acetic acid at ~₹340 vs FY24 average of ~₹450); Specialties declined 18% due to an anticipated agro AI product phase-out (~9% of sales) and deferred deliveries (~4%) shifting to H2. Ethyl acetate spreads fell to ~$120/MT, well below the 12-year ex-COVID average of $220-225. Capex deployment is on track with ₹680 crores of the ₹750 crore FY26 plan already spent; Dahej mechanical completion is targeted for end Q3/early Q4 FY26. Management is pursuing the Hitachi Energy SF6-replacement LOI (contract expected in Q2) within the existing ₹1,100 crore capex envelope, while the Lote Fluoro site targets 40-60% of peak revenues in FY26.
Near-term pressure on margins and revenues likely persists through Q2-Q3 FY26 given sub-₹120 spreads, Specialties product phase-out, and muted demand in coatings/agro. Management views current levels as cyclical bottom and flags potential upside from Chinese capacity moderation, Sipchem mothballing a 100,000 MT ethyl acetate plant, and tariff-driven rerouting. Stock may react cautiously as management declined to give explicit full-year FY26 or FY27 revenue/EBITDA guidance.